This company has been marked as potentially delisted and may not be actively trading. OvaScience (OVAS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock OVAS vs. ZYME, SBTX, MBX, AVTE, NLTX, CYBN, BIOA, VIRI, WHWK, and PYRGFShould you be buying OvaScience stock or one of its competitors? The main competitors of OvaScience include Zymeworks (ZYME), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), Cybin (CYBN), BioAge Labs (BIOA), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), and PyroGenesis Canada (PYRGF). OvaScience vs. Its Competitors Zymeworks Silverback Therapeutics MBX Biosciences Aerovate Therapeutics Neoleukin Therapeutics Cybin BioAge Labs Virios Therapeutics Whitehawk Therapeutics PyroGenesis Canada OvaScience (NASDAQ:OVAS) and Zymeworks (NYSE:ZYME) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership. Which has preferable valuation and earnings, OVAS or ZYME? OvaScience has higher earnings, but lower revenue than Zymeworks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOvaScience$290K921.70-$50.97MN/AN/AZymeworks$93.38M9.40-$118.67M-$1.49-8.46 Which has more risk & volatility, OVAS or ZYME? OvaScience has a beta of 3.11, suggesting that its share price is 211% more volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Do insiders & institutionals hold more shares of OVAS or ZYME? 22.5% of OvaScience shares are held by institutional investors. Comparatively, 92.9% of Zymeworks shares are held by institutional investors. 7.4% of OvaScience shares are held by insiders. Comparatively, 1.9% of Zymeworks shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media refer more to OVAS or ZYME? In the previous week, Zymeworks had 2 more articles in the media than OvaScience. MarketBeat recorded 2 mentions for Zymeworks and 0 mentions for OvaScience. Zymeworks' average media sentiment score of 0.35 beat OvaScience's score of 0.00 indicating that Zymeworks is being referred to more favorably in the news media. Company Overall Sentiment OvaScience Neutral Zymeworks Neutral Is OVAS or ZYME more profitable? Zymeworks has a net margin of -182.75% compared to OvaScience's net margin of -10,128.37%. Zymeworks' return on equity of -23.00% beat OvaScience's return on equity.Company Net Margins Return on Equity Return on Assets OvaScience-10,128.37% -47.06% -42.39% Zymeworks -182.75%-23.00%-18.04% Do analysts rate OVAS or ZYME? Zymeworks has a consensus target price of $21.00, suggesting a potential upside of 66.67%. Given Zymeworks' stronger consensus rating and higher probable upside, analysts clearly believe Zymeworks is more favorable than OvaScience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OvaScience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Zymeworks 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90 SummaryZymeworks beats OvaScience on 11 of the 15 factors compared between the two stocks. Get OvaScience News Delivered to You Automatically Sign up to receive the latest news and ratings for OVAS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OVAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OVAS vs. The Competition Export to ExcelMetricOvaSciencePharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$267.29M$763.12M$5.51B$9.35BDividend YieldN/A4.84%4.74%4.16%P/E RatioN/A1.3529.1824.41Price / Sales921.7025.03435.00101.08Price / CashN/A19.5624.4827.20Price / Book4.146.578.485.77Net Income-$50.97M-$4.20M$3.24B$264.99M OvaScience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OVASOvaScienceN/A$7.46-0.4%N/A+374.1%$267.29M$290K0.00N/AGap DownZYMEZymeworks3.0655 of 5 stars$12.94-4.2%$21.00+62.3%+23.5%$901.70M$93.38M-8.63460Upcoming EarningsSBTXSilverback TherapeuticsN/A$17.75-3.3%N/A+73.5%$640.03MN/A-7.3383High Trading VolumeMBXMBX Biosciences2.627 of 5 stars$15.49+3.5%$37.57+142.6%N/A$517.74MN/A0.0036News CoveragePositive NewsGap UpHigh Trading VolumeAVTEAerovate TherapeuticsN/A$7.75-6.4%N/A-88.6%$224.63MN/A-2.5920News CoverageUpcoming EarningsHigh Trading VolumeNLTXNeoleukin TherapeuticsN/A$21.68-4.6%N/A-44.9%$203.75MN/A-6.9790Gap DownCYBNCybin2.874 of 5 stars$7.30-3.6%$85.00+1,064.4%N/A$172.21MN/A-1.6750News CoverageBIOABioAge LabsN/A$4.42-1.3%N/AN/A$158.46MN/A0.00N/APositive NewsVIRIVirios TherapeuticsN/A$4.82+1.0%$5.00+3.7%+2,466.1%$92.82MN/A-17.855Upcoming EarningsWHWKWhitehawk TherapeuticsN/A$1.79+1.1%N/AN/A$84.33M$27.78M11.1940PYRGFPyroGenesis Canada0.3734 of 5 stars$0.29-0.5%N/A-48.0%$53.95M$9.14M-4.8090 Related Companies and Tools Related Companies ZYME Competitors SBTX Competitors MBX Competitors AVTE Competitors NLTX Competitors CYBN Competitors BIOA Competitors VIRI Competitors WHWK Competitors PYRGF Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OVAS) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OvaScience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OvaScience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OVAS Stock Alerts